Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 09

43P - Looking for therapeutic targets on the proteome profile of endometrial cancer stem cells

Date

21 Oct 2023

Session

Poster session 09

Topics

Cancer Biology;  Cancer Research

Tumour Site

Endometrial Cancer

Presenters

Mafalda Laranjo

Citation

Annals of Oncology (2023) 34 (suppl_2): S187-S214. 10.1016/S0923-7534(23)01931-2

Authors

M. Laranjo1, C. Mestre1, B. Serambeque1, A.S. Carvalho2, H. C. Beck3, M.F. Botelho4, M.J. Carvalho5, R. Matthiesen2

Author affiliations

  • 1 Coimbra Institute For Clinical And Biomedical Research (icbr), Area Of Environment, Genetics And Oncobiology Research (cimago), Institute Of Biophysics, Faculty Of Medicine; Cibb; Cacc, Univ Coimbra, 3004-504 - Coimbra/PT
  • 2 Inova4health, Nova Medical School (nms), Faculdade De Ciências Médicas (fcm), Universidade Nova de Lisboa, 1150-082 - Lisboa/PT
  • 3 Clinical Biochemistry, Odense Universitetshospital, 5000 - Odense/DK
  • 4 Coimbra Institute For Clinical And Biomedical Research (icbr), Area Of Environment, Genetics And Oncobiology Research (cimago), Institute Of Biophysics, Faculty Of Medicine; Institute Of Experimental Pathology; Cibb; Cacc, Univ Coimbra, 3000-370 - Coimbra/PT
  • 5 Gynecology Service, CHUC - Centro Hospitalar e Universitário de Coimbra, EPE, 3000-075 - Coimbra/PT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 43P

Background

Endometrial cancer (EC) is one of the most frequent gynaecological malignant diseases whose incidence presents an increasing trend. Cancer stem cells (CSC), a subpopulation of undifferentiated tumour cells identified in EC, are the main actors in the resistance mechanisms to conventional therapies. Thus, the main aim of this study is to identify novel molecular targets in endometrial CSC for the future development of innovative targeted therapies for EC.

Methods

Two EC cell lines, ECC-1 and RL95-2, were cultured, and endometrial CSC were obtained through an optimized 5-day sphere formation assay. A proteomic profile of cell lines and endometrial CSC was determined through mass spectrometry-based proteomics. The analysis was performed through the comparison of CSC vs. cell line proteins significantly up-regulated by a 40-fold change and their cellular localization. R package was used for statistical analysis.

Results

The proteomic analysis of ECC-1 samples allowed the identification of 477 up-regulated ECC-1-CSC-specific proteins, 108 ECC-1-specific proteins, and 2306 common proteins. Regarding RL95-2 samples, the analysis identified 76 up-regulated RL95-2-CSC-specific, 994 cell line-specific, and 1420 common proteins. The cellular localization of up-regulated proteins identified from CSC populations was mainly the cytoplasm (25-31%), nucleus (19-23%), and membrane (21-22%). Regarding the functional analysis, the more regulated subcategories were the intracellular ferritin complex, poly(A) RNA binding, (acetyl-CoA carboxylase) kinase activity, (hydroxymethylglutaryl-CoA reductase (NADPH)) kinase activity, and ubiquitinyl hydrolase activity for ECC-1-CSC vs. ECC-1; the proteasome, cytosol, extracellular vesicular exosome, poly(A) RNA binding, glutamate dehydrogenase (NAD+) activity, and glutamate dehydrogenase (NADP+) activity for RL95-2-CSC vs. RL95-2; and poly(A) RNA binding, (acetyl-CoA carboxylase) kinase activity, NADPH kinase activity, and ubiquitinyl hydrolase activity for both.

Conclusions

CSC population-specific proteins were identified, as well as their cellular localization and functional enrichment. This information allows for the future development of endometrial CSC targeted therapies.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Univ Coimbra.

Funding

Centre for Innovative Biomedicine and Biotechnology (CIBB) (UIDB/04539/2020, UIDP/04539/2020) is supported by The Fundação para a Ciência e a Tecnologia (FCT), co-funded by COMPETE. Beatriz Serambeque was awarded a PhD Scholarship from FCT and European Social Fund (2020.07672. BD ).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.